Skip Navigation


In video briefs and interviews, experts in the field offer their perspectives on developments in health security and background on the issues addressed in our articles and reports. 



Find multimedia by keywords:

Find multimedia by mission area, year, or author or view all:

The FDA's Evolving Role in MCM Development
Video feature
February 05, 2014

Luciana Borio, MD, Assistant Commissioner for Counterterrorism Policy and Director, Office of Counterterrorism and Emerging Threats in the Office of the Chief Scientist, US Food and Drug Administration


In this interview, Dr. Borio outlines the evolving role that the Food Drug Administration (FDA) has assumed in the development of medical countermeasures. Under Dr. Borio's leadership, the FDA has established the Medical Countermeasure Initiative (MCMi), which is an effort to hasten the development of these products, and to improve their odds of achieving FDA approval. The MCMi has made investments in improving the regulatory science that will be necessary for government's ability to evaluate a new generation of medical products. Here, Dr. Borio discusses some of the successes that the FDA has achieved in this arena, such as the ability to evaluate and approve multiplex diagnostic assays, as well as the challenges that remain.